简要报告：晚期非小细胞肺癌患者的靶向治疗和胰腺炎。

IF 3.3 3区医学 Q2 ONCOLOGY

Clinical lung cancer Pub Date : 2024-09-03 DOI:10.1016/j.cllc.2024.08.016

May-Lucie Meyer , Louis Gros , Natalie Décosterd , Marco Tagliamento , Arianna Marinello , David Planchard , David Combarel , Fabrice Barlesi , Jordi Remon , Benjamin Besse , Mihaela Aldea

{"title":"简要报告：晚期非小细胞肺癌患者的靶向治疗和胰腺炎。","authors":"May-Lucie Meyer , Louis Gros , Natalie Décosterd , Marco Tagliamento , Arianna Marinello , David Planchard , David Combarel , Fabrice Barlesi , Jordi Remon , Benjamin Besse , Mihaela Aldea","doi":"10.1016/j.cllc.2024.08.016","DOIUrl":null,"url":null,"abstract":"<div><div><ul><li><span></span><span><div>Targeted treatments are commonly used to treat lung cancer but can induce elevations in pancreatic enzyme levels in up to 24% of patients. While these drugs are recognized as potential triggers for pancreatitis, the clinical significance of monitoring pancreatic enzymes and the incidence of clinical acute pancreatitis remains uncertain. In our study of 1207 targeted treatments in 725 patients with advanced lung cancer, we observed that, although elevations in pancreatic enzymes were frequent (37%), instances of clinical acute pancreatitis were scarce (0.08%). Based on our findings and in line with the current recommendations of drug-induced pancreatitis, we suggest that routine monitoring for pancreatitis is not necessary in asymptomatic patients.</div></span></li></ul></div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"25 8","pages":"Pages e482-e486.e3"},"PeriodicalIF":3.3000,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Brief Report: Targeted Therapies and Pancreatitis in Patients With Advanced Nonsmall Cell Lung Cancer\",\"authors\":\"May-Lucie Meyer , Louis Gros , Natalie Décosterd , Marco Tagliamento , Arianna Marinello , David Planchard , David Combarel , Fabrice Barlesi , Jordi Remon , Benjamin Besse , Mihaela Aldea\",\"doi\":\"10.1016/j.cllc.2024.08.016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div><ul><li><span></span><span><div>Targeted treatments are commonly used to treat lung cancer but can induce elevations in pancreatic enzyme levels in up to 24% of patients. While these drugs are recognized as potential triggers for pancreatitis, the clinical significance of monitoring pancreatic enzymes and the incidence of clinical acute pancreatitis remains uncertain. In our study of 1207 targeted treatments in 725 patients with advanced lung cancer, we observed that, although elevations in pancreatic enzymes were frequent (37%), instances of clinical acute pancreatitis were scarce (0.08%). Based on our findings and in line with the current recommendations of drug-induced pancreatitis, we suggest that routine monitoring for pancreatitis is not necessary in asymptomatic patients.</div></span></li></ul></div></div>\",\"PeriodicalId\":10490,\"journal\":{\"name\":\"Clinical lung cancer\",\"volume\":\"25 8\",\"pages\":\"Pages e482-e486.e3\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2024-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical lung cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1525730424001943\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical lung cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1525730424001943","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

靶向治疗常用于治疗肺癌，但在多达 24% 的患者中会引起胰酶水平升高。虽然这些药物被认为是胰腺炎的潜在诱因，但监测胰酶的临床意义和临床急性胰腺炎的发病率仍不确定。在我们对 725 名晚期肺癌患者进行的 1207 次靶向治疗研究中，我们观察到，虽然胰酶升高很常见（37%），但临床急性胰腺炎的发生率却很低（0.08%）。基于我们的研究结果，并根据目前对药物诱发胰腺炎的建议，我们建议对无症状患者不必进行胰腺炎的常规监测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Brief Report: Targeted Therapies and Pancreatitis in Patients With Advanced Nonsmall Cell Lung Cancer

查看原文本刊更多论文

Brief Report: Targeted Therapies and Pancreatitis in Patients With Advanced Nonsmall Cell Lung Cancer

Targeted treatments are commonly used to treat lung cancer but can induce elevations in pancreatic enzyme levels in up to 24% of patients. While these drugs are recognized as potential triggers for pancreatitis, the clinical significance of monitoring pancreatic enzymes and the incidence of clinical acute pancreatitis remains uncertain. In our study of 1207 targeted treatments in 725 patients with advanced lung cancer, we observed that, although elevations in pancreatic enzymes were frequent (37%), instances of clinical acute pancreatitis were scarce (0.08%). Based on our findings and in line with the current recommendations of drug-induced pancreatitis, we suggest that routine monitoring for pancreatitis is not necessary in asymptomatic patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical lung cancer 医学-肿瘤学

CiteScore

7.00

自引率

2.80%

发文量

159

审稿时长

24 days

期刊介绍： Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.